2026-06-30 · 8 min
GLP-1, Ozempic and your oral health: five years of evidence (2020-2026)
If you are being treated with Ozempic, Wegovy or any other GLP-1 receptor agonist, there is something most of your doctors probably are not telling you: these medications also affect your mouth. And not trivially.
Over the last five years a specific body of evidence has been built on how GLP-1 agonists (GLP-1RAs) intersect with your periodontal health, your alveolar bone regeneration and your oral microbiome. The findings are fascinating and, at the same time, counter-intuitive.
This article synthesizes the evidence available today, with the same rigor we bring to every patient at AS Odontología Digital. We will walk through the four most important papers in chronological order, draw the concrete clinical implications, and be honest about what we still do not know.
One note up front: no paper in Nature, Lancet or JAMA has addressed this topic yet. The field is emerging, and that is important information too.
What are GLP-1RAs, and why should they matter to your dentist?
GLP-1 receptor agonists (glucagon-like peptide 1) are a family of medications originally designed to treat type 2 diabetes. The best known are:
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Liraglutide (Saxenda, Victoza)
- Tirzepatide (Mounjaro, Zepbound), technically a dual GLP-1/GIP agonist
- Dulaglutide (Trulicity)
They work by lowering blood glucose, reducing appetite and, as discovered in recent years, modulating systemic inflammation and several regenerative processes in tissues you would never suspect. Among them, your periodontal tissues.
GLP-1 receptors are not only in your pancreas. They are also in your gums, in your alveolar bone and in the mesenchymal stem cells of your bone marrow. That anatomical detail is what opens this whole conversation.
The arc of evidence: five years in four papers
2020: the foundational proof (Sawada et al., J Diabetes Res)
The first study to specifically address GLP-1 and periodontitis was published by Sawada and colleagues in 2020, in the Journal of Diabetes Research. They used an animal model of periodontitis and evaluated the effect of liraglutide. They found two important things:
- Liraglutide significantly reduced the alveolar bone loss induced by experimental periodontitis.
- It decreased pro-inflammatory M1 macrophages in the gingival tissue, favoring the anti-inflammatory M2 phenotype.
But the most important detail, and the one often omitted, is this: these effects occurred independently of glucose control. The periodontal benefit was not a byproduct of better metabolic control, but a direct anti-inflammatory effect of GLP-1 on the periodontal tissues. This raises the possibility that GLP-1RAs may have periodontal applications even in non-diabetic patients.
2025: the first clinical confirmation in humans (Ahmad, Miron et al., JRE)
In 2025, the group led by Richard Miron, one of the global references in regenerative periodontology, published in the Journal of Periodontal Research the first robust clinical analysis in humans. The findings: in patients with type 2 diabetes, GLP-1 agonists were associated with better periodontal health and better peri-implant health. The effect was seen in soft tissues (less bleeding, shallower probing depth) and in bone markers. It is the first clinical evidence confirming in humans what Sawada had shown in animals five years earlier.
June 2026: the emerging consensus (Sufaru et al., Biomolecules)
In June 2026, Biomolecules published a structured narrative review (SANRA) consolidating the emerging consensus on GLP-1RAs in periodontology. The review organizes the effects into two pathways.
Indirect pathway:
- Better glycemic control, which lowers systemic inflammation and RANKL/osteoclast activation.
- Weight loss, which reduces pro-inflammatory cytokines (TNF-α, IL-6).
- Less gingival vascular endothelial dysfunction.
Direct (mechanistic) pathway:
- Activation of GLP-1 receptors on periodontal fibroblasts, osteoblasts and mesenchymal stem cells.
- Modulation of the NF-κB (inflammation), Wnt/β-catenin (osteogenesis) and MAPK (cell proliferation) pathways.
- Reduced osteoclastic activity through inhibition of RANK signaling.
The review also mentions the known oral adverse effects: xerostomia, dehydration and increased caries risk from reduced salivary flow.
May 2026: the mechanistic nuance (Jiang et al., Materials Today Bio)
Almost in parallel, a team published in Materials Today Bio a mechanistic study that introduces a critical nuance. In an animal model of obesity plus periodontitis treated with semaglutide, they found that:
- Semaglutide reduced periodontal inflammation and osteoclast markers, consistent with Sawada 2020.
- But it did not regenerate the alveolar bone already lost.
The mechanistic reason? In the bone marrow mesenchymal stem cells (BMSCs), AMPK signaling was suppressed and fatty-acid oxidation stayed switched off. In other words, the bone stem cells are left without the energy metabolism needed to regenerate bone.
The editorial conclusion almost no one is drawing: anti-inflammation is not the same as regeneration. GLP-1s can protect the bone you still have, but they will not give you back the bone you have already lost.
The oral side effects almost no one will mention
Beyond the nuance about regeneration, there are two documented and under-communicated adverse effects.
Xerostomia (dry mouth). GLP-1RAs reduce salivary flow in a significant percentage of users. Saliva is your first line of defense against caries, acid erosion and oral dysbiosis. Without it, your mouth becomes a far more vulnerable environment.
Systemic dehydration. Because of reduced appetite, many patients on GLP-1 take in less total fluid. That worsens the xerostomia and compromises the enamel's natural protection.
Combined, these two effects can significantly increase the risk of cervical caries, erosion and periodontitis, paradoxically in patients whose metabolic control is improving.
Clinical protocol if you are on a GLP-1RA
Based on the consolidated evidence, this is the protocol we apply at AS Odontología Digital for patients being treated with GLP-1RAs.
1. Periodontal check-up every 6 months, not every 12. Subclinical periodontitis advances silently. At twice the frequency, we catch it before it becomes irreversible.
2. Specific xerostomia assessment. We measure stimulated and unstimulated salivary flow, and adjust the hygiene and remineralization plan if we detect a decrease.
3. Deliberate hydration. We give a quantified recommendation, not generic advice: between 2 and 3 liters of water a day, adjusted for body mass and activity.
4. Oral microbiome test as a baseline. At AS we offer oral microbiome analysis in partnership with Eternal Smile, the first test of its kind available in Chile. It sets a baseline and lets us monitor changes in the microbiome while the patient is on GLP-1.
5. Specific restorative management. Preferential use of biocompatible materials with remineralizing properties in patients with reduced salivary flow.
6. Clear expectations. We explain that GLP-1s can protect current bone, but do not regenerate bone already lost. That clinical decision (regeneration with biomaterials, grafts and other techniques) is independent of the drug therapy.
What we still do not know
It is worth saying plainly: no paper in Nature, Lancet or JAMA has yet specifically addressed GLP-1 and oral health. The available evidence is solid, but preliminary. Still missing:
- Randomized controlled clinical trials in humans with periodontal endpoints.
- Long-term studies (more than five years) on regenerative effects.
- Data specific to each GLP-1RA (semaglutide vs. liraglutide vs. tirzepatide).
- Dose-response analysis and therapeutic windows.
This is a field under active construction. At AS Odontología Digital we are monitoring the literature in real time and updating our protocols as the evidence evolves.
Conclusion
GLP-1 agonists are rewriting the clinical manual for diabetes, obesity and, increasingly clearly, oral health. The available evidence suggests they are imperfect allies: they reduce periodontal inflammation and protect existing tissues, but they produce xerostomia and do not regenerate lost bone.
If you are being treated with a GLP-1RA, your dentist should know about it, and should have a specific protocol for you. This is not a generic clinical situation.
At AS Odontología Digital we integrate your full metabolic context into every treatment plan. If you are on a GLP-1RA and want a specific evaluation that includes periodontal analysis, salivary flow measurement and an oral microbiome test, message us and we will arrange it.
References
- Sawada N, Adachi K, Nakamura N, et al. GLP-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis. J Diabetes Res. 2020;2020:8843310. DOI: 10.1155/2020/8843310
- Ahmad P, Estrin N, Farshidfar N, Zhang Y, Miron RJ. Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) Improve Periodontal and Peri-Implant Health in Type 2 Diabetes Mellitus. J Periodontal Res. 2025. DOI: 10.1111/jre.13410
- Sufaru IG, Vasiliu BC, Solomon SM, et al. GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care. Biomolecules. 2026;16(6):857. DOI: 10.3390/biom16060857
- Jiang T, Wan TH, Ouyang NJ, et al. Met@MPDA rejuvenates BMSC energy metabolism to promote bone regeneration in semaglutide-treated obese periodontitis. Materials Today Bio. 2026. DOI: 10.1016/j.mtbio.2026.103231
Last updated: June 2026. This article is updated as new evidence becomes available.
